HeartSciences Launches Breakthrough ECG Technology in Middle East

MyoVista® hsECG™ Utilizes Wavelet Technology to Detect Cardiac Diastolic Dysfunction

SOUTHLAKE, Texas, Oct. 19, 2017 /PRNewswire/ — HeartSciences announced today the commercial launch of its MyoVista® high sensitivity electrocardiograph (hsECG™) Testing Device in the Middle East. The MyoVista hsECG is now available for commercial sale in the first markets of United Arab Emirates (UAE) and Kuwait and will soon extend to other countries in the region.

HeartSciences

The MyoVista hsECG was developed using Continuous Wavelet Transform mathematics and goes beyond conventional ECG technology with new metrics to detect repolarization abnormalities. This new capability enables physicians to detect diastolic dysfunction which is typically diagnosed using tissue Doppler echocardiography. As an early manifestation of many types of heart disease, diastolic dysfunction has become a significant area of interest in cardiology. Coronary artery disease (CAD), hypertrophy, cardiomyopathy and valvular diseases are examples of diseases that will cause diastolic dysfunction.

The MyoVista hsECG, incorporates all of the capabilities of a full featured 12-lead resting ECG plus new proprietary informatics that assist in detecting diastolic dysfunction. Using machine learning, MyoVista hsECG technology detected diastolic dysfunction with 88 percent sensitivity, and 87 percent specificity, in a recent clinical trial at Mount Sinai Hospital in New York.*

“The MyoVista hsECG represents an exciting breakthrough in ECG technology,” said Mark Hilz, Chief Executive Officer, HeartSciences. “We look forward to introducing this breakthrough technology to the Gulf region.”

In the region, MyoVista will be sold via distribution partners. The device is also available across the European Union, where it received the CE (Conformité Européenne) Mark approval earlier this year. HeartSciences is also in the process of expanding distribution to Canada, Australia, Latin America and Asia-Pacific. HeartSciences expects to seek U.S. Food and Drug Administration clearance for MyoVista in 2018.

About HeartSciences
HeartSciences is advancing the field of electrocardiology through the patented use of wavelet mathematics and artificial intelligence to develop medical devices that significantly improve the early detection of heart disease. HeartSciences is bridging today’s “diagnostic gap” in cardiac care by developing new low-cost effective solutions that help to identify at-risk patients prior to the occurrence of an adverse cardiac event, such as a heart attack. The company’s first device, the MyoVista, features the capabilities of a full featured 12-lead resting ECG plus new proprietary informatics that assist in detecting diastolic dysfunction.

Significant focus from the cardiology community is now being placed on diastolic dysfunction since it begins in the early stages of heart disease when patients often do not present with any symptoms. Coronary artery disease (CAD), hypertrophy, cardiomyopathy and valvular diseases are examples of diseases that will cause diastolic dysfunction. HeartSciences (formerly known as Heart Test Laboratories) is a privately-held U.S. corporation based in Southlake, Texas, and to date has been funded by private investors.

*Data on file at HeartSciences

For more information or to find a local distributor, visit www.heartsciences.com.

Logo – http://mma.prnewswire.com/media/584238/HeartSciences_Logo.jpg

Related Post
بنغالور ووارين، نيوجيرسي، 11 ديسمبر 2017 /PRNewswire-FirstCall/ — تم الإعلان عن إطلاق لقب “النجم الصاعد”
ABU DHABI, United Arab Emirates, Dec. 12, 2017 /PRNewswire/ — The Louvre in Abu Dhabi demands
Amsterdam, December 12, 2017 at 07:00 AM – The board of Gemalto N.V. (the Company)